Jeffrey Capello, executive vice president and chief financial officer, divulged that Biogen intends to exercise its option to increase its stake in the Samsung Bioepis joint venture. Currently, Samsung BioLogics holds 94.6% of the company, and Biogen owns the remaining 5.4%.
Biogen, one partner in the biosimilar development company Samsung Bioepis, reported total revenues of $3.1 billion in its first quarter 2018 business update call. While most of Biogen’s earnings—up 11% from the same period in 2017—derived from its drugs targeting multiple sclerosis, Jeffrey Capello, executive vice president and chief financial officer, said that biosimilars brought in $128 million in revenues, up from $66 million in the first quarter of 2017.
Approximately 80,000 patients are now taking Biogen’s biosimilars, said Capello, and the uptake of Benepali, a European Medicines Agency—approved etanercept biosimilar referencing Enbrel, is estimated to have produced an €800 million (approximately $970 million) annual savings in Europe.
Biogen sees the potential for even greater biosimilar growth ahead; earlier this month, together with Samsung, Biogen reached an agreement with AbbVie, the maker of the reference adalimumab (Humira). The settlement ended patent litigation over the reference drug and will allow commercialization of Samsung Bioepis’ approved adalimumab biosimilar, Imraldi, in Europe beginning in October 2018. Capello said that the adalimumab biosimilar will be a growth driver for the business in the days ahead.
Capello also divulged that Biogen intends to exercise its option to increase its stake in the Samsung Bioepis joint venture. Currently, Samsung BioLogics holds 94.6% of the company, and Biogen owns the remaining 5.4%. According to Reuters, Biogen has the option to increase its stake in the joint company to as much as 49.9%. That investment, says Korean media outlet The Investor, could be worth as much as $370 million.
Currently, Samsung Bioepis’ pipeline includes etanercept, infliximab (approved and launched in the United States as Renflexis), adalimumab, insulin glargine (tentatively approved in the United States as a follow-on insulin product), trastuzumab (for which a Biologics License Application was filed with the FDA in late 2017), and bevacizumab.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.